JANXHealthcare · BiotechnologyThe 18 Wall Street analysts covering Janux Therapeutics, Inc. hold a median 12-month price target of $32 — +98.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 71 of 100 as at 15 Aug 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Janux Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (94): Sales and profits are climbing, and climbing faster than before.
Momentum (15): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on JANX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +98.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | Guggenheim | Maintains | Buy | $58 → $55 |
| 25 June 2026 | Truist Securities | Assumes | Buy | $80 → $26 |
| 8 May 2026 | Guggenheim | Maintains | Buy | — |
| 8 May 2026 | Piper Sandler | Maintains | Overweight | — |
| 8 May 2026 | Wedbush | Maintains | Outperform | — |
| 28 Apr 2026 | Jones Trading | Maintains | Buy | — |
| 20 Apr 2026 | Barclays | Downgrade | Underweight | — |
| 15 Apr 2026 | UBS | Downgrade | Neutral | — |
| 27 Feb 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 27 Feb 2026 | Guggenheim | Maintains | Buy | — |
| 20 Jan 2026 | Clear Street | Downgrade | Hold | — |
| 16 Jan 2026 | Piper Sandler | Maintains | Overweight | — |
| 17 Dec 2025 | Barclays | Maintains | Overweight | — |
| 2 Dec 2025 | B of A Securities | Maintains | Buy | — |
| 2 Dec 2025 | Cantor Fitzgerald | Maintains | Overweight | — |
| 2 Dec 2025 | Clear Street | Maintains | Buy | — |
| 2 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Dec 2025 | Stifel | Maintains | Buy | — |
| 25 Nov 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Nov 2025 | Wolfe Research | Initiates | Peer Perform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. JANX appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 92% of US stocks
Cheaper than 6% of US stocks
Cheaper than 73% of US stocks
Cheaper than 62% of US stocks
Higher than 96% of US stocks
Higher than 9% of US stocks
Higher than 30% of US stocks
Higher than 35% of US stocks
Higher than 27% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Janux Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Janux Therapeutics reported a Q2 loss of $0.35 per share, wider than the Zacks Consensus Estimate of a $0.26 loss, though an improvement from the $0.55 per share loss in the year-ago quarter.
Why it matters — The quarterly results missed analyst estimates, giving JANX watchers an updated view of the company's recent financial performance.
Janux Therapeutics reported its financial results for the quarter ended June 30, 2026, and provided a business update. CEO David Campbell said the company continued to execute across its clinical portfolio while preparing for multiple upcoming milestones, with patient enrollment progressing.
Why it matters — JANX watchers would care because the update signals ongoing clinical trial enrollment and highlights upcoming pipeline milestones for the immunotherapy developer.
The 18 Wall Street analysts covering Janux Therapeutics, Inc. have a median 12-month price target of $32, with estimates ranging from $14 to $72. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 18 analysts covering Janux Therapeutics, Inc., 15 rate it a Buy, 2 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Janux Therapeutics, Inc. 71 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Janux Therapeutics, Inc. ranks 71 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (94 of 100).
No one can know that. What the data says: the median 12-month target from 18 analysts implies +98.5% from the last close, and Ticker Nerd's factor model ranks Janux Therapeutics, Inc. 71 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Janux Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JANX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $72 over the next 12 months.
Janux Therapeutics, Inc. returned -35.4% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Janux Therapeutics Inc. is a clinical-stage biopharmaceutical company developing precision-engineered immunotherapies for cancer and autoimmune diseases.
The most recent item we track (Zacks Investment Research, 6 Aug 2026): "Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates". Janux Therapeutics reported a Q2 loss of $0.35 per share, wider than the Zacks Consensus Estimate of a $0.26 loss, though an improvement from the $0.55 per share loss in the year-ago quarter.
Janux Therapeutics Inc. is a clinical-stage biopharmaceutical company developing precision-engineered immunotherapies for cancer and autoimmune diseases. It pioneers next-generation T cell engagers using proprietary TRACTr, TRACIr, and ARM platforms to create drug candidates that selectively activate immune responses in tumors, minimizing systemic safety issues and overcoming limitations of traditional immunotherapies. Key clinical programs include JANX007, a PSMA-targeted TRACTr in Phase 1 trials for metastatic castration-resistant prostate cancer and other tumors, and JANX008, an EGFR-targeted therapy in Phase 1 for solid tumors such as colorectal cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. The company maintains a strategic research collaboration with Merck Sharp & Dohme Corp. to advance TRACTr candidates. Focused on oncology and immunology, Janux Therapeutics Inc. aims to deliver safe, effective treatments that guide the immune system against disease. Incorporated in 2017 and headquartered in San Diego, California, it operates at the forefront of immunotherapy innovation.
CEO Dr. David Alan Campbell Ph.D. · 113 employees · United States · https://www.januxrx.com